Early combination therapy in type 2 diabetes: Rethinking initial treatment strategies
Abstract
For decades, type 2 diabetes (T2D) pharmacotherapy has followed a reactive, stepwise approach, typically initiated with metformin monotherapy and intensified only after glycemic deterioration. This so-called wait-to-fail strategy may prolong hyperglycemia and increase the cumulative risk of microvascular and macrovascular complications. Early combination therapy (ECT) has been proposed as an alternative strategy to achieve faster glycemic control, improve glycemic durability, and enable timely use of glucose-lowering agents with cardiovascular, renal, and metabolic benefits. This narrative review examines the rationale for ECT in newly diagnosed T2D and summarizes evidence from landmark clinical trials. Recent updates to major international guidelines, including the 2026 American Diabetes Association Standards of Care in Diabetes and National Institute for Health and Care Excellence NG28, are also discussed, reflecting a shift toward individualized, comorbidity-focused treatment selection. While ECT represents an important evolution in T2D management, current clinical evidence supports its use mainly in selected patients rather than as a universal default strategy.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.